Loading...
•
Sep 30, 2022
OptimizeRx Q3 2022 Earnings Report
OptimizeRx reported Q3 2022 financial results, with a focus on growth in Real World Evidence (RWE) solutions and reiteration of full-year financial outlook.
Key Takeaways
OptimizeRx reported its Q3 2022 financial results, highlighting momentum in Real World Evidence (RWE) solutions. The company reiterated its full-year financial outlook for net revenue between $62 million and $68 million and gross margins between 59% and 62%.
OptimizeRx is seeing significant momentum off the mid-year trough.
The company is gaining traction across its business, particularly with Real World Evidence (RWE) solutions.
OptimizeRx believes executing on RWE opportunities could position them to grow topline by over 20% next year.
The company reiterated its full-year financial outlook for 2022 for net revenue to be between $62 million and $68 million and gross margins to be between 59% and 62%.
Forward Guidance
OptimizeRx reiterated its full year 2022 financial outlook.
Positive Outlook
- Net revenue to be between $62 million and $68 million.
- Year-over-year growth of 1% to 11%, respectively.
- Gross margins to be between 59% and 62%.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...